CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 68 enrolled
Drug / intervention
SIM1910-09 +1 moredrug
Likely dose
SIM1910-09 2mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05200728
NCT05200728Phase 1Completed

A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Tolerability, Safety, and PK Characteristics of SIM1910-09 After Single/Multiple Dosing in Healthy Chinese Volunteers

Jiangsu Simcere Pharmaceutical Co., Ltd.·interventional·Posted Jan 21, 2022·Updated Nov 30, 2023

In Brief

A Phase 1 clinical trial evaluating SIM1910-09 and Placebo for Acute Ischemic Stroke and Cerebral Edema. Completed, enrolled 68 participants across 1 site.

Detailed Summary

This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the tolerability, safety, and pharmacokinetic characteristics of SIM1910-09 for injection after single/multiple dosing in healthy Chinese adult volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedJan 21, 2022
Enrollment StartDec 6, 2021
Primary CompletionMar 23, 2023
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 4.4 years ago

Interventions

SIM1910-09drug

Part A-single ascending doses, SIM1910-09 will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose. Part B-multiple ascending doses, SIM1910-09 will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion;4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion;4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion;4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion,which will be tested sequentially from low dose to high dose.

Placebodrug

Part A-single ascending doses, placebo will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose. Part B-multiple ascending doses, placebo will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion;4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion;4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion;4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion,which will be tested sequentially from low dose to high dose.